...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Reactions to prick and intradermal skin tests.
【24h】

Reactions to prick and intradermal skin tests.

机译:对刺和皮内皮肤测试的反应。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Allergy skin testing is a common procedure for the diagnosis of atopic diseases with a small risk of systemic reactions. OBJECTIVE: To determine the 12-month incidence of systemic reactions (SRs) to skin prick testing (SPT) and intradermal skin testing (ST) and the symptoms and response to immediate treatment with epinephrine intramuscularly. METHODS: A prospective study was conducted to evaluate SRs from ST in 1,456 patients. A standard form was used to record symptoms, signs, and treatment. The SRs are defined as any sign or symptom other than a local reaction thought to be secondary to ST. No vasovagal reactions were included. Nurses, as instructed by attending physicians, administered epinephrine (0.2 mL of a 1:1,000 dilution) intramuscularly in the deltoid as soon as any remote signs or symptoms occurred. RESULTS: Fifty-two patients (3.6%) had SRs (6 SPT and 46 intradermal): 43 (83%) were female, and 17 (33%) had asthma. Systemic symptoms included (SPT/intradermal) pruritic eyes, nose, or pharynx (0%/46%); worsening cough (50%/26%); sensation of difficulty swallowing (0%/20%); worsening nasal congestion (17%/15%); rhinorrhea (17%/13%); chest tightness or shortness of breath (33%/11%); generalized pruritus (17%/11%); sneezing (33%/9%); wheeze (0%/4%); and urticaria (17%/2%). No severe asthma, shock, hypotension, unconsciousness, or biphasic reactions occurred. All 52 patients received epinephrine intramuscularly, 48 (92%) oral prednisone, 9 (17%) oral prednisone to take 6 to 8 hours after a reaction, 50 (96%) oral antihistamine, and 6 (12%) nebulized beta-agonist. CONCLUSIONS: Of patients who underwent ST, SRs occurred in 3.6% (0.4% for SPT and 3.2% for intradermal ST), all of whom readily responded to epinephrine intramuscularly in the deltoid. This immediate administration of epinephrine seems to prevent more serious and biphasic reactions.
机译:背景:过敏性皮肤测试是诊断全身性疾病风险较小的特应性疾病的常用方法。目的:确定对皮肤点刺试验(SPT)和皮内皮肤试验(ST)的全身反应(SR)的12个月发生率,以及肌注肾上腺素的症状和对立即治疗的反应。方法:进行了一项前瞻性研究,以评估1,456例患者的ST SR。使用标准表格记录症状,体征和治疗。 SR被定义为除了被认为是ST继发的局部反应以外的任何体征或症状。不包括血管迷走神经反应。一旦出现任何遥远的体征或症状,护士应按照主治医师的指示,在三角肌中肌内注射肾上腺素(0.2 mL的1:1,000稀释液)。结果:52例患者(3.6%)有SR(6个SPT和46个皮内):女性43例(83%),哮喘17例(33%)。全身症状包括(SPT /皮内)瘙痒性眼,鼻或咽(0%/ 46%);咳嗽加重(50%/ 26%);吞咽困难感(0%/ 20%);鼻塞恶化(17%/ 15%);鼻漏(17%/ 13%);胸闷或气短(33%/ 11%);全身性瘙痒(17%/ 11%);打喷嚏(33%/ 9%);喘息(0%/ 4%);和荨麻疹(17%/ 2%)。没有发生严重的哮喘,休克,低血压,神志不清或双相反应。所有52例患者均肌肉注射肾上腺素,反应后6至8小时服用48(92%)口服泼尼松,9(17%)口服泼尼松,50(96%)口服抗组胺药和6(12%)雾化的β-激动剂。结论:接受ST治疗的患者中,SR的发生率为3.6%(SPT为0.4%,皮内ST为3.2%),所有这些患者在三角肌中都容易对肾上腺素作出反应。立即给予肾上腺素似乎可以预防更严重和双相的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号